December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

69.59 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Why Mark Minervini may look into TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) ↗
A fundamental and technical analysis of (NASDAQ:TARS): Why the high growth investor may take a look at TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). 
Via Chartmill
News headline image
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Tarsus Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
An Overview of Tarsus Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Would Mark Minervini consider TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) a top stock pick? ↗
Exploring high growth characteristics of TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). A fundamental and technical analysis of (NASDAQ:TARS). 
Via Chartmill
News headline image
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run ↗
The company sells one drug to treat a condition that causes dry, red and itchy eyes. But rosacea and Lyme disease could be next. 
Via Investor's Business Daily
News headline image
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company’s newly created Medical Organization 
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.